Visão geral da empresa
A biotechnology enterprise, Moderna, Inc. specializes in the development and commercialization of messenger RNA (mRNA) medicines across the United States, Europe, and international markets. The company operates within the broader Healthcare sector, specifically focusing on the Biotechnology industry, which is characterized by high research and development expenditures and significant regulatory hurdles. Moderna maintains a substantial operational footprint with a workforce of 4,700 employees and holds a market capitalization of $20.66B. This valuation, combined with a Trailing Twelve Months (TTM) revenue of $1.94B, indicates that the market assigns a significant premium to the company's intellectual property and pipeline potential, despite the current challenges in generating profitability typical for early-stage biopharma entities.
Saúde financeira
Moderna reported a TTM revenue of $1.94B alongside a net income of $-2,822,000,128 and an EBITDA of $-2,859,000,064. The substantial negative gap between the positive revenue figure and the deeply negative net income reveals an extremely aggressive cost structure where operating expenses and research costs vastly exceed total sales revenue. The company's free cash flow stands at $-1,326,499,968, indicating a continuous burn rate that limits immediate financial flexibility without external capital injections or significant future revenue expansion. Analysis of the three primary margins shows a Gross Margin of -105.8%, an Operating Margin of -126.4%, and a Profit Margin of -145.2%, all of which signify that the company is currently losing money on every unit sold and in its overall operations. Regarding liquidity and leverage, Moderna holds $5.80B in cash against $1.30B in debt, supported by a Debt to Equity ratio of 15.09, which suggests a conservative balance sheet structure where cash reserves significantly outweigh debt obligations despite the negative earnings. The Current Ratio is 3.29, demonstrating robust short-term liquidity as current assets are more than three times current liabilities. Furthermore, the Return on Equity is -28.9% and the Return on Assets is -14.5%, metrics that reveal management is currently destroying shareholder value and utilizing assets inefficiently to generate positive returns in the present period.
Avaliação de valorização
The valuation metrics present a complex picture with a Trailing P/E Ratio (TTM) of N/A and a Forward P/E of -11.22. The absence of a trailing P/E and the negative forward multiple imply that the market cannot value the stock based on current earnings and expects earnings to remain negative or turn positive only in the future, reflecting the company's loss-making status. The Price to Book ratio is 2.37, indicating that the market prices the company at more than double its net asset value, suggesting a high premium placed on the intangible value of the mRNA pipeline. Alternative valuation measures include a Price to Sales ratio of 10.63 and an EV/EBITDA of -5.62, which suggest that investors are willing to pay a significant multiple of sales despite the lack of profitability, betting on future commercial success. The stock price has ranged between a 52-Week Low of $22.28 and a 52-Week High of $59.55, meaning the current trading price sits at a specific point within this volatile range determined by market sentiment and recent earnings reports. The Beta value is 1.34, which indicates that the stock's price volatility is 34% higher than the broader market, exposing investors to greater fluctuations in share price relative to the overall market index.
Growth & Income
Moderna's financial trajectory shows a Revenue Growth (YoY) of -29.8% and an Earnings Growth (YoY) of N/A. The decline in revenue is evident in the negative growth rate, while the lack of earnings growth data reinforces the company's current inability to generate profits. Since the earnings are negative, they are not growing faster than revenue in a traditional sense; rather, the company is contracting in revenue while maintaining heavy fixed costs, which implies a challenging path to breakeven. As a non-dividend payer, the company has a Dividend Yield of N/A and a Payout Ratio of 0.0%, meaning it does not distribute any cash to shareholders but instead retains all capital to fund research and development. Consequently, the overall growth and income profile is defined by a contraction in top-line sales and a complete absence of income generation or dividend distribution, relying entirely on future pipeline milestones to reverse the negative trends observed in the available financial data.